

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



July 8, 2026

Company name: TAUNS Laboratories, Inc.
Representative: Masaki Nonaka, President and CEO
(Code no.: 197A, Standard Market, Tokyo Stock Exchange)
Contact person: Yoshio Uchiyama, Director and CFO
Tel: +81-55-953-9590

Notice Concerning the Execution of a Business Alliance Agreement with Craif, Inc.

TAUNS Laboratories, Inc. (headquartered in Izunokuni-shi, Shizuoka, Japan; Masaki Nonaka, President and CEO; Securities Code: 197A; hereinafter referred to as "TAUNS") hereby announces that it has entered into a business alliance agreement with Craif, Inc. (headquartered in Shinjuku-ku, Tokyo, Japan; Ryuichi Onose, CEO; hereinafter referred to as "Craif"), including exclusive sales rights for a portion of future products currently under development, as set forth below.

1. Purpose and Background of the Business Alliance

Through this alliance, the Company and Craif seek to expand the sales and market penetration of Craif's products, promote the growth of their respective businesses, and maximize profitability.

2. Details of the Business Alliance

(1) Sales Collaboration

Pursuant to this Agreement, the Company will be granted sales rights in Japan as one of Craif's sales partners for "miSignal Scan" (hereinafter, "miSignal"), a product provided by Craif, for sales to medical institutions through pharmaceutical wholesalers, medical device distributors, and other distribution channels.

In addition, the Company will be granted exclusive sales rights in Japan for a Software as a Medical Device (SaMD) for assisting in the diagnosis of pancreatic cancer based on urinary microRNA analysis (hereinafter, the "Pancreatic Cancer SaMD"), which is currently under development by Craif, for sales to medical institutions through the same distribution channels.

Furthermore, during the term of this Agreement, the Company will be granted preferential negotiation rights with respect to other SaMD products for various cancer types that are related to or derived from the Pancreatic Cancer SaMD, as well as any new SaMD products that may be commercialized in the future.

(2) Scope of Business Cooperation

-The Company will conduct sales activities in Japan targeting medical institutions through pharmaceutical wholesalers, medical device distributors, and other distribution channels.

-Craif will provide the Company with technical support and other assistance necessary for the supply of miSignal and the Pancreatic Cancer SaMD currently under development by Craif.

-The Company and Craif will jointly conduct marketing activities for miSignal and the Pancreatic Cancer SaMD currently under development by Craif.

(3) Term of Exclusive Sales Rights for the Product Under Development

The term of the exclusive sales rights for the Pancreatic Cancer SaMD shall initially continue until June 30 of the year following the year in which commercial sales commence. The term may be renewed upon satisfaction of certain conditions specified in the Agreement.

3. Overview of Craif Inc.

(1) Name	Craif, Inc.
(2) Address	B1F THE PORTAL iidabashi, 8-30 Shin-ogawamachi, Shinjuku-ku, Tokyo 162-0814, Japan
(3) Title and name of representative	Ryuichi Onose, CEO
(4) Business	Research and development of next-generation diagnostic technologies, with a focus on early detection and personalized medicine for cancer and other diseases. Provider of miSignal® (available only in Japan), a non-invasive cancer risk testing service based on urinary microRNA analysis.
(5) Date of establishment	May 2018
(6) Relationship with the Company	The Company and Craif entered into a capital and business alliance agreement in April 2025.
(7) Corporate site	https://craif.com/en

4. Comments from Both Companies

Comment from Masaki Nonaka, President and CEO of TAUNS Laboratories, Inc.

In April 2025, TAUNS entered into a capital and business alliance agreement with Craif and has since been working toward a sales partnership for miSignal, a cancer risk screening test utilizing microRNA technology.

In our Mid-Term Management Plan, we have identified expansion into the chronic disease field as one of our key growth strategies. In this context, we regard Craif as an extremely important strategic partner in achieving this objective.

We believe that the grant of sales rights, including exclusive rights, for the Pancreatic Cancer SaMD currently under development by Craif represents a significant initiative that will further strengthen the collaboration between our two companies. We take seriously the confidence and expectations that Craif has placed in us and are committed to playing an active role in promoting early screening for pancreatic cancer, an area of considerable social importance.

By leveraging this newly acquired sales right and our established sales network serving medical institutions, we will work to accelerate the adoption of Craif's products and contribute to the early detection of cancer.

Comment from Ryuichi Onose, CEO of Craif, Inc.

At Craif, we have created value by enabling the early detection of cancer through our technology that combines AI with the analysis of urinary microRNA. However, to deliver this value broadly to medical institutions across Japan, a strong distribution partner is essential. In this regard, we are especially encouraged to partner with TAUNS, which has built an extensive distribution network in the field of rapid diagnostics over many years and has earned a high level of trust from healthcare providers.

This agreement represents an important step toward accelerating the commercialization and market adoption of our Pancreatic Cancer SaMD, which is currently under development, subject to obtaining the necessary regulatory approvals. We believe that developing an innovative diagnostic solution is only part of the challenge; its true value can be realized only when it is successfully delivered to the patients and healthcare providers who need it.

Together with TAUNS, we will work to advance the standard of early cancer detection in Japan and contribute to improving healthcare outcomes through broader access to innovative diagnostic technologies.

5. Outlook

At this time, the Company believes that the impact of the execution of this Agreement on its financial results will be immaterial. However, if it becomes apparent that the Agreement is expected to have a material impact on the Company's business performance, the Company will promptly disclose such information.

6. Other Matters

Certain details of this Agreement have not been disclosed in accordance with the mutual agreement of the parties.